Salarius Pharmaceuticals Valuation
| SLRX Stock | USD 2.69 0.07 2.67% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Salarius Pharmaceuticals has a current Real Value of $2.16 per share. The regular price of the company is $2.69. Our model measures the value of Salarius Pharmaceuticals from inspecting the company fundamentals such as Shares Owned By Institutions of 0.36 %, return on equity of -1.2, and Shares Outstanding of 1.44 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Salarius Pharmaceuticals' valuation include:
Price Book 1.3256 | Enterprise Value | Enterprise Value Ebitda 1.5245 | Price Sales 18.1198 | Enterprise Value Revenue 0.1368 |
Overvalued
Today
Please note that Salarius Pharmaceuticals' price fluctuation is abnormally volatile at this time. Calculation of the real value of Salarius Pharmaceuticals is based on 3 months time horizon. Increasing Salarius Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Salarius Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Salarius Stock. However, Salarius Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.69 | Real 2.16 | Target 3.13 | Hype 2.69 |
The intrinsic value of Salarius Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Salarius Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Salarius Pharmaceuticals helps investors to forecast how Salarius stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Salarius Pharmaceuticals more accurately as focusing exclusively on Salarius Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Salarius Pharmaceuticals' intrinsic value based on its ongoing forecasts of Salarius Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Salarius Pharmaceuticals' closest peers.
Salarius Pharmaceuticals Cash |
|
Salarius Valuation Trend
Analysing the historical paterns of Salarius Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Salarius Pharmaceuticals over time and is usually enough for investors to make rational market timing decisions.
Salarius Pharmaceuticals Total Value Analysis
Salarius Pharmaceuticals is at this time projected to have valuation of 921.53 K with market capitalization of 3.88 M, debt of 289.64 K, and cash on hands of 22.65 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Salarius Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
921.53 K | 3.88 M | 289.64 K | 22.65 M |
Salarius Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Salarius is to check how much profit was generated for every dollar of assets it reports. Salarius Pharmaceuticals has a negative utilization of assets of -0.54 %, losing $0.005399 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Salarius Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Salarius Pharmaceuticals Ownership Allocation
About 97.12 % of Salarius Pharmaceuticals outstanding shares are held by general public with 2.52 (%) owned by insiders and only 0.36 % by institutional holders.Salarius Pharmaceuticals Profitability Analysis
Net Loss for the year was (12.54 M) with loss before overhead, payroll, taxes, and interest of (15.84 M).About Salarius Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Salarius Pharmaceuticals. We calculate exposure to Salarius Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Salarius Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -9 K | -8.6 K | |
| Pretax Profit Margin | (6.24) | (6.56) | |
| Operating Profit Margin | (6.27) | (6.58) | |
| Net Loss | (6.21) | (6.52) | |
| Gross Profit Margin | 0.89 | 0.59 |
Salarius Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 3.3 M |
Salarius Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Salarius Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Salarius we look at many different elements of the entity such as Salarius's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Salarius Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Salarius Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Salarius Pharmaceuticals' worth.Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.